Factors in sustained compliance to a symptom-reporting mobile application: implications for clinical implementation

Implementation of electronic prospective surveillance models in cancer care: a scoping review

“…While publication years ranged from 2005 to 2021, the majority were published in the last 5 years ( n = 43, 68%). Of the 46 interventions included, nearly half ( n = 22, 48%) were conducted in Europe [ 27 – 48 ], followed by North America ( n = 20, 43%) [ 14 , 15 , 49 – 66 ], Australia ( n = 3, 7%) [ 67 – 69 ], and the Philippines ( n = 1, 2%) [ 70 ]. Most interventions targeted patients with a mix of cancer types ( n = 24, 52%) [ 14 , 15 , 27 , 30 , 35 , 37 , 40 , 41 , 46 , 47 , 51 , 52 , 54 , 55 , 60 – 63 , 65 – 70 ], followed by a focus on head and neck ( n = 4, 8%) [ 31 , 32 , 48 , 53 ], gynecologic ( n = 3, 7%) [ 49 , 57 , 58 ], lung ( n = 3, 7%) [ 39 , 56 , 59 ], and breast ( n = 3, 7%) [ 28 , 42 , 64 ] cancers.…”

“…Most interventions targeted patients with a mix of cancer types ( n = 24, 52%) [ 14 , 15 , 27 , 30 , 35 , 37 , 40 , 41 , 46 , 47 , 51 , 52 , 54 , 55 , 60 – 63 , 65 – 70 ], followed by a focus on head and neck ( n = 4, 8%) [ 31 , 32 , 48 , 53 ], gynecologic ( n = 3, 7%) [ 49 , 57 , 58 ], lung ( n = 3, 7%) [ 39 , 56 , 59 ], and breast ( n = 3, 7%) [ 28 , 42 , 64 ] cancers. Of the 46 ePSM studies, 33% ( n = 15) explicitly used implementation science in their design, data collection, or analysis [ 30 , 32 , 35 , 41 , 44 , 46 , 50 , 51 , 53 – 55 , 58 , 60 , 67 , 69 ], while 67% ( n = 31) reported on the implementation of an ePSM but did not use an implementation science approach [ 14 , 15 , 27 – 29 , 31 , 33 , 34 , 37 – 40 , 42 , 43 , 47 – 49 , 52 , 56 , 57 , 59 , 61 – 66 , 68 , …”

“…Of the 46 ePSM studies, 33% ( n = 15) explicitly used implementation science in their design, data collection, or analysis [ 30 , 32 , 35 , 41 , 44 , 46 , 50 , 51 , 53 – 55 , 58 , 60 , 67 , 69 ], while 67% ( n = 31) reported on the implementation of an ePSM but did not use an implementation science approach [ 14 , 15 , 27 – 29 , 31 , 33 , 34 , 37 – 40 , 42 , 43 , 47 – 49 , 52 , 56 , 57 , 59 , 61 – 66 , 68 , 70 – 72 ]. Overall, 57% ( n = 26) used a non-randomized experimental or quality improvement design [ 29 , 31 – 34 , 37 – 39 , 41 , 43 , 44 , 47 – 50 , 52 , 55 – 59 , 62 , 64 , 65 , 67 , 68 ], 26% ( n = 12) used a randomized experimental design [ 14 , 15 , 27 , 28 , 35 , 40 , 42 , 46 , 54 , 70 , 71 , 73 ], 9% ( n = 4) were descriptive case reports on the implementation of the inte...…”

“…Notably, 30% ( n = 14) of the studies included an additional qualitative component to their design [ 29 , 31 , 32 , 35 , 38 , 39 , 42 , 45 , 48 , 50 , 51 , 67 – 69 ]. Within included studies, 41% ( n = 19) focused exclusively on patients on active treatment [ 14 , 15 , 27 , 29 , 37 , 40 , 41 , 44 , 45 , 47 , 50 , 54 – 57 , 61 , 62 , 64 , 65 ], 39% ( n = 18) included patients during active treatment as well as follow-up surveillance [ 28 , 30 , 31 , 33 , 34 , 38 , 39 , 43 , 51 – 53 , 58 , 60 , 63 , 66 – 69 ], 11% ( n = 5) were exclusively during follow-up surveillance [ 32 , 36 , 42 , 46 , 48 ], 4% ( n = 2) during the postoperative period [ 49 , 59 ], and 4% ( n = 2) during palliative care [ 35 , 70 ].

Fig.

…”

“…Most interventions did not have a fixed (e.g., weekly or monthly) surveillance schedule for patients ( n = 25, 54%), with most asking patients to complete ePROs at any outpatient visit [ 14 , 15 , 28 , 30 – 34 , 36 , 41 , 46 , 48 , 51 – 53 , 56 – 58 , 60 , 61 , 63 , 64 , 66 , 69 , 70 ]. Some interventions allowed clinicians to personalize the frequency of reporting for patients or asked patients to report based on their preference ( n = 3, 7%) [ 28 , 46 , 70 ].…”